Table 4: Genes associated with T-cell receptor signaling pathway.

SymbolGenBank accessionGene descriptionlog2 FCa
M/NSH/MSM/MSL/MOseltamivir/M

Cd3g PH_mM_0008250CD3 antigen, gamma polypeptide, CD3 1.261.43−0.500.17−0.49
Cd247 PH_mM_0012514CD247 antigen, CD3ζ1.560.38−1.59−0.65−1.10
Ptprc PH_mM_0012802Protein tyrosine phosphatase, receptor type, C. CD451.650.32−1.41−0.11−0.52
Rasgrp1 PH_mM_0009315RAS guanyl releasing protein 12.43−0.93−1.94−1.25−1.60
Ctla4 mMC018651Cytotoxic T-lymphocyte-associated protein 41.590.67−1.94−0.49−1.01
Ikbkb mMR027870Inhibitor of kappaB kinase beta1.33−0.65−0.87−0.67−1.19
Mapk1 mMC024552Mitogen-activated protein kinase 1, Erk2.23−0.90−1.04−0.47−1.50
Map3k8 mMC012006Mitogen-activated protein kinase kinase kinase 8, COT3.59−2.86−3.98−2.92−3.09
Nfkbie PH_mM_0006219Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, epsilon. IκBε4.26−1.84−3.75−2.32−3.13
Nfkbib mMC008604Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, beta. IκBβ3.34−2.35−2.68−2.12−2.88
Nfkbia mMC012597Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha. IκB 1.66−0.92−1.95−1.33−1.52
Zap70 mMC019091Zeta-chain associated protein kinase, ZAP-701.530.38−1.36−0.58−1.49
Pik3r5 PH_mM_0003125Phosphoinositide-3-kinase, regulatory subunit 5, p101. PI3K3.12−2.52−3.90−2.95−2.88
Pik3cg mMC005200Phosphoinositide-3-kinase, catalytic, gamma polypeptide. PI3K1.64−0.75−1.49−1.25−1.21
Map2k1 PH_mM_0006215Mitogen-activated protein kinase kinase 11.76−0.53−1.00−0.81−1.06
Pik3cd PH_mM_0001034Phosphatidylinositol 3-kinase catalytic delta polypeptide. PI3K1.42−0.27−2.08−0.74−0.96

Fold change. The intensity ratio of probe signal criteria for differential expressions was defined as a twofold change (up or down) (log2 FC ≥ 1 or ≤−1) in gene expression compared with virus control group and a value less than 0.05 in at least one time point as a minimum requirement to select. For instance, log2 (M/N) ≥ 1 means that the comparison between normal control group and virus control group was scattered, indicating that a large number of genes in virus control group were up-regulated in response to H1N1 infection. log2 (SH/M) ≤ −1, log2 (SM/M) ≤ −1, log2 (SL/M) ≤ −1, and log2 (Oseltamivir/M) ≤ −1 means that down-regulation in gene expression attributable to the high-dose SFXF group treatment, medium-dose group SFXF treatment, low-dose SFXF group treatment and Oseltamivir group treatment was done by comparing genes in virus control group, respectively ( value data not shown).